Two Sigma Investments LP Boosts Stock Holdings in Definitive Healthcare Corp. (NASDAQ:DH)

Two Sigma Investments LP raised its stake in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 2,383.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 285,555 shares of the company's stock after purchasing an additional 274,055 shares during the period. Two Sigma Investments LP owned 0.25% of Definitive Healthcare worth $1,174,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Bayesian Capital Management LP bought a new position in shares of Definitive Healthcare in the 4th quarter worth about $41,000. Ieq Capital LLC bought a new position in shares of Definitive Healthcare in the 4th quarter worth about $51,000. KLP Kapitalforvaltning AS bought a new position in shares of Definitive Healthcare in the 4th quarter worth about $54,000. Two Sigma Securities LLC bought a new position in shares of Definitive Healthcare in the 4th quarter worth about $56,000. Finally, ProShare Advisors LLC raised its position in shares of Definitive Healthcare by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,018 shares of the company's stock worth $62,000 after acquiring an additional 4,943 shares in the last quarter. 98.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DH. BTIG Research lowered Definitive Healthcare from a "buy" rating to a "neutral" rating in a research report on Friday, May 9th. Barclays decreased their target price on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research report on Monday, March 3rd. The Goldman Sachs Group boosted their target price on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research report on Monday, May 12th. Finally, Wall Street Zen lowered Definitive Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, May 31st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $5.10.

Definitive Healthcare Stock Up 5.1%

DH traded up $0.18 during midday trading on Friday, reaching $3.74. 694,978 shares of the company were exchanged, compared to its average volume of 794,265. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. The company's fifty day moving average price is $2.93 and its 200 day moving average price is $3.74. The company has a market cap of $555.92 million, a price-to-earnings ratio of -1.21, a price-to-earnings-growth ratio of 4.06 and a beta of 1.58. Definitive Healthcare Corp. has a one year low of $2.15 and a one year high of $6.27.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.03. The firm had revenue of $59.19 million during the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The company's revenue for the quarter was down 6.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 EPS. As a group, analysts expect that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.